Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.61 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18183654 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BBCHETAAR1 | |
| SCHEMBL1009815 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1B | |
| SCHEMBL12071546 | 0.81 | MTNR1A (0.59) | MTNR1AMTNR1B | |
| SCHEMBL5017858 | 0.79 | FABP4 (0.59) | BCHEABCB1ABCG2 | |
| SCHEMBL19692664 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BBRD4TAAR1 | |
| SCHEMBL32661221 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BBRD4TAAR1 | |
| SCHEMBL16210197 | 0.78 | KMT2A (0.68) | MTNR1AMTNR1B | |
| SCHEMBL17583904 | 0.78 | ABCB1 (0.58) | BCHEABCB1ABCG2TAAR1 | |
| SCHEMBL1010724 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL30028243 | 0.77 | MTNR1A (0.86) | MTNR1AMTNR1BBCHEABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | Boehringer Ingelheim International GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| WO-2016041845-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | MTNR1A 1415/4885MTNR1B 1904/4885BCHE 3071/4885 |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | QDPR, RECQL, TPMT | MTNR1A 353/4885MTNR1B 182/4885BCHE 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.